From cigarettes to compulsions: a longitudinal study in de novo Parkinson's disease
In conclusion, the novelty of our findings lies in showing that smoking-related influences on impulsive-compulsive behaviors in PD are most evident at the de novo stage, before any dopaminergic treatment. This temporal specificity may help resolve previous inconsistencies in the literature and underscores the importance of distinguishing between environmental and pharmacological effects on symptom development.
Authors
- Elisa Di Rosa (ORCID: https://orcid.org/0000-0001-9902-4595)
- Luca Vedovelli (ORCID: https://orcid.org/0000-0003-4847-2333)
- Patrizia Bisiacchi (ORCID: https://orcid.org/0000-0003-2760-8000)
- Fabio Masina (ORCID: https://orcid.org/0000-0003-2296-4970)
- Matilde Massara
- Nicky Edelstyn
Institutions
- University of Padua (IT)
- IRCCS San Camillo Hospital (IT)
- Bath Spa University (GB)
Publication Details
- Journal
- Frontiers in Psychology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.3389/fpsyg.2025.1708535
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Celgene
- Jazz Pharmaceuticals
- Neurocrine Biosciences
- Verily Life Sciences
- Università degli Studi di Padova
- Servier
- H. Lundbeck A/S
- Sun Pharma
- Genentech
- Allergan
- Avid Radiopharmaceuticals